Efficacy of Sacubitril/Valsartan Relative to a Prior Decompensation: The PARADIGM-HF Trial

JACC: Heart Failure

Volumn 4, Issue 10, 2016, Pages 816-822

  Solomon, Scott D ^a   Claggett, Brian ^a   Packer, Milton ^b   Desai, Akshay ^a   Zile, Michael R ^c   Swedberg, Karl ^d   Rouleau, Jean ^e   Shi, Victor ^f   Lefkowitz, Martin ^f   McMurray, John J V ^g  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f NOVARTIS PHARMA AG   (Switzerland)

^g UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

heart failure; neprilysin inhibition; renin angiotensin system

Indexed keywords

ENALAPRIL; SACUBITRIL PLUS VALSARTAN; AMINOBUTYRIC ACID DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MEMBRANE METALLOENDOPEPTIDASE; TETRAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; DRUG EFFICACY; FEMALE; HEART DEATH; HEART FAILURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; SCREENING; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG SUBSTITUTION; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; AMINOBUTYRATES; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG SUBSTITUTION; ENALAPRIL; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NEPRILYSIN; TETRAZOLES; TREATMENT OUTCOME;

EID: 84991633745     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2016.05.002     Document Type: Article

References (9)

1. 1 Vardeny, O., Miller, R., Solomon, S.D., Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. J Am Coll Cardiol HF 2 (2014), 663–670.
2. 2 McMurray, J.J., Packer, M., Desai, A.S., et al., PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371 (2014), 993–1004.
3. 3 Simpson, J., Jhund, P.S., Cardoso, J.S., et al. Effect of LCZ696, compared with enalapril, according to baseline risk in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). J Am Coll Cardiol 66 (2015), 2059–2071.
4. 4 Solomon, S.D., Claggett, B., Desai, A., et al. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: the PARADIGM-HF trial. Circ Heart Fail, 9, 2016, e002744.
5. 5 Murray A. PL Detail-Document, New Drug: Entresto (Sacubitril/Valsartan). Pharmacist's Letter/Prescriber's Letter. September 2015. Available at: http://prescribersletter.therapeuticresearch.com/pl/ArticlePDF.aspx?cs=&s=PRL&DocumentFileID=0&DetailID=310919&SegmentID=0%20usg=AFQjCNHlwDjwIfMoXThziRtRcxAQR0tlrg. Accessed May 26, 2016.
6. 6 Bello, N.A., Claggett, B., Desai, A.S., et al. Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circ Heart Fail 7 (2014), 590–595.
7. 7 McMurray, J.J., Packer, M., Desai, A.S., et al., PARADIGM-HF Committees and Investigators. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail 15 (2013), 1062–1073.
8. 8 Aujoulat, I., Jacquemin, P., Rietzschel, E., et al. Factors associated with clinical inertia: an integrative review. Adv Med Educ Pract 8 (2014), 141–147.
9. 9 Giugliano, D., Esposito, K., Clinical inertia as a clinical safeguard. JAMA 305 (2011), 1591–1592.